Selvadurai, Louisa P.
Perlman, Susan L.
Wilmot, George R.
Subramony, Sub H.
Gomez, Christopher M.
Ashizawa, Tetsuo
Paulson, Henry L.
Onyike, Chiadi U.
Rosenthal, Liana S.
Sair, Haris I.
Kuo, Sheng-Han
Ratai, Eva-Maria
Zesiewicz, Theresa A.
Bushara, Khalaf O.
Öz, Gülin
Dietiker, Cameron
Geschwind, Michael D.
Nelson, Alexandra B.
Opal, Puneet
Yacoubian, Talene A.
Nopoulos, Peggy C.
Shakkottai, Vikram G.
Figueroa, Karla P.
Pulst, Stefan M.
Morrison, Peter E.
Schmahmann, Jeremy D. http://orcid.org/0000-0003-0706-5125
Funding for this research was provided by:
National Ataxia Foundation
MINDlink Foundation
Fulbright Australia
National Institute of Neurological Disorders and Stroke (U01 NS104326)
Article History
Accepted: 25 May 2022
First Online: 12 August 2022
Declarations
:
: E.M.R. serves on the BrainSpec Inc. Scientific Advisory Board. G.Ö. consults for IXICO Technologies Limited and uniQure biopharma B.V., serves on the Scientific Advisory Board of BrainSpec Inc., and receives research support from Biogen. J.D.S. is site PI for Biohaven Pharma, consults for Biogen and MedAvante, and holds the copyright with the General Hospital Corporation to the Brief Ataxia Rating scale, Patient Reported outcome Measure of Ataxia, and the Cerebellar Cognitive Affective/Schmahmann Syndrome Scale.